Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Regor Therapeutics.

    Client Virtual Booth

    REGOR THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Regor Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    245 Main Street, Second Floor, Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.regor.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

    Details:

    RGT-075 is an oral-available, once-daily, small molecule GLP-1R full agonist, which is being evaluated in phase 2 clinical trials for the treatment of Obesity.


    Lead Product(s): RGT-075

    Therapeutic Area: Nutrition and Weight Loss Product Name: RGT-075

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On ...

    Details:

    RGT-419B is a small molecule CDK4 inhibitor currently undergoing Phase I clinical trial evaluation with patients for treating HR-positive/HER2-negative Breast Neoplasms.


    Lead Product(s): RGT-419B

    Therapeutic Area: Oncology Product Name: RGT-419B

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 07, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Building a New Generation AI Engine and Jointly Accelerating World-Class Innovative Drug Discovery and Development

    Details:

    In this collaboration, NVIDIA will contribute its industry-leading GPU products and high performance computing to the rCARDTM platform, including NVIDIA Clara Discovery and the AutoDock-GPU suite.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: NVIDIA Corporation

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 24, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

    Details:

    Under the terms of the agreement, Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan, where Regor will maintain these rights and responsibilities.


    Lead Product(s): Undisclosed

    Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Eli Lilly

    Deal Size: $1,550.0 million Upfront Cash: $50.0 million

    Deal Type: Collaboration December 10, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search